Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Parabilis Medicines

Parabilis Medicines Presents Clinical Data Demonstrating First-Ever Drugging of Key Cancer Driver with FOG-001
From Parabilis Medicines
Via Business Wire
Parabilis Medicines Appoints Fawzi Benzaghou, M.D., as Chief Medical Officer
From Parabilis Medicines
Via Business Wire
Parabilis Medicines to Present Overview of Ongoing Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at Upcoming Medical Meetings
From Parabilis Medicines
Via Business Wire
Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program
From Parabilis Medicines
Via Business Wire
Parabilis Medicines to Present First Preclinical Data on ERG Degrader Program at AACR Annual Meeting
From Parabilis Medicines
Via Business Wire
Parabilis Medicines to Present Trial-in-Progress Poster on Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at ASCO Gastrointestinal Cancers Symposium
From Parabilis Medicines
Via Business Wire
Parabilis Medicines Presents Updates on Clinical Progress of β-cateninTCF4 Inhibitor, Helicon™ Portfolio and Discovery Engine at J.P. Morgan Healthcare Conference
From Parabilis Medicines
Via Business Wire
Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform
From Parabilis Medicines
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.